

MANUFACTURER OF BULK DRUGS & IMPORTERS OF SOLVENTS & CHEMICALS

H.O: 203/4 SAHAKAR BHAVAN, 340/48 N.N STREET, MUMBAI-400009 🗭 : (022) 23455543 Email: corporate@aareydrugs.com REGD OFF. & FACTORY: E-34 MIDC, TARAPUR, BOISAR, DIST.-THANE 🗭 (02525) 271049 Email: info@aareydrugs.com CIN: L99999MH1990PLC056538

Date:- 11th November, 2023

To,	
BSE Limited	National Stock Exchange of India Limited
The Manager,	Exchange Plaza
Corporate Service Department	Bandra Kurla Complex,
P.J. Towers, Dalal Street,	Bandra (E),
Mumbai- 400 001	Mumbai – 400051
Scrip Code: 524412	NSE Symbol: AAREYDRUGS

Sub: Disclosure under Regulation 23(9) of the SEBI (Listing Obligations & Disclosure Requirements), Regulations 2015, for the quarter and year ended 30th September, 2023.

Dear Sir/Madam,

Pursuant to the provisions of Regulation 23(9) of the SEBI (Listing Obligations & Disclosure Requirements), Regulations 2015, please find enclosed herewith disclosure of Related Party Transactions for the quarter and year ended 30th September, 2023.

Please take on record of the same and oblige.

Thanking You,

Yours faithfully, For Aarey Drugs & Pharmaceuticals Limited

Nimit Rajesh Digitally signed by Nimit Rajesh Ghatalia Ghatalia Date: 2023.11.11 23:14:31 +05'30'

Nimit Rajesh Ghatalia Director DIN: 07069841

Encl.: a/a

												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.							
<u>Srno</u>	Details of the party (listed entity/subsidiary) entering into the transaction		Details of the counterparty		<u>d</u>	<u>Valu</u> <u>e of</u> <u>Relat</u> <u>ed</u> party	<u>Valu</u> <u>e of</u> <u>Tran</u> <u>sacti</u> on	In case monies are due to either party		In case any			<u>details</u>						
	<u>Name</u>	PAN	Name	PAN	Relationshi p of the counterpar ty with the listed entity or its subsidiary	ction	trans actio n as appr oved by the audit com mitte e	on durin g the repo rting perio d	O p n ba la n e	p g e balanc ni e ng balanc ba balanc ba balanc la balanc	<u>Natur</u> <u>e of</u> <u>indebt</u> <u>ednes</u> <u>s</u> (loan/ <u>issuan</u> <u>ce of</u> <u>debt/</u> <u>any</u> <u>other</u> <u>etc)</u>	<u>cos</u> <u>t</u>	<u>tenur</u> <u>e</u>	Natur e (Loan /adva nce/ inte corpo rate depos ed/inv estme nt	Interes trate (%)	tenur e	<u>Secured/u</u> <u>n</u>	Purpos e for which the funds will be utilized by the ultimat e recipie nt of funds (end usage)	
<u>1.</u>	<u>Mihir R</u>							<u>3000</u>											

	<u>Ghatali</u>				<u>00</u>					
	<u>a</u>									
<u>2.</u>	<u>Rajesh</u>				<u>1800</u>					
	<u>Ghatali</u>				<u>00</u>					
	<u>a</u>									
<u>3.</u>	<u>Nimit</u>				<u>1500</u>					
	<u>Ghatali</u>				<u>00</u>					
	<u>a</u>									
<u>4.</u>	<u>Mira M</u>				1200					
	<u>Ghatali</u>				<u>00</u>					
	<u>a</u>									
<u>5.</u>	<u>RENT</u>				<u>2661</u>					
					<u>360</u>					